Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

Bibliographic Details
Main Authors: Weinblatt, Michael E., Fleischmann, Roy, van Vollenhoven, Ronald F., Emery, Paul, Huizinga, Tom WJ, Cutolo, Maurizio, van der Heijde, Désirée, Duncan, Benjamin, Davies, Owen, Luijtens, Kristel, Dougados, Maxime
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644627/
id pubmed-4644627
recordtype oai_dc
spelling pubmed-46446272015-11-16 Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population Weinblatt, Michael E. Fleischmann, Roy van Vollenhoven, Ronald F. Emery, Paul Huizinga, Tom WJ Cutolo, Maurizio van der Heijde, Désirée Duncan, Benjamin Davies, Owen Luijtens, Kristel Dougados, Maxime Research Article BioMed Central 2015-11-15 2015 /pmc/articles/PMC4644627/ /pubmed/26568428 http://dx.doi.org/10.1186/s13075-015-0841-9 Text en © Weinblatt et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Weinblatt, Michael E.
Fleischmann, Roy
van Vollenhoven, Ronald F.
Emery, Paul
Huizinga, Tom WJ
Cutolo, Maurizio
van der Heijde, Désirée
Duncan, Benjamin
Davies, Owen
Luijtens, Kristel
Dougados, Maxime
spellingShingle Weinblatt, Michael E.
Fleischmann, Roy
van Vollenhoven, Ronald F.
Emery, Paul
Huizinga, Tom WJ
Cutolo, Maurizio
van der Heijde, Désirée
Duncan, Benjamin
Davies, Owen
Luijtens, Kristel
Dougados, Maxime
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
author_facet Weinblatt, Michael E.
Fleischmann, Roy
van Vollenhoven, Ronald F.
Emery, Paul
Huizinga, Tom WJ
Cutolo, Maurizio
van der Heijde, Désirée
Duncan, Benjamin
Davies, Owen
Luijtens, Kristel
Dougados, Maxime
author_sort Weinblatt, Michael E.
title Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
title_short Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
title_full Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
title_fullStr Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
title_full_unstemmed Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
title_sort twenty-eight-week results from the realistic phase iiib randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
description
publisher BioMed Central
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644627/
_version_ 1613501116262121472

Similar Items